查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423565

到 2030 年藥物基因體學技術市場預測：按類型、治療領域、技術、分銷管道、最終用戶和地區進行的全球分析

Pharmacogenomics Technologies Market Forecasts to 2030 - Global Analysis By Type, Therapeutic Area, Technology, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球藥物基因體學技術市場規模為 68 億美元，預計預測期內複合年成長率為 10.7%，到 2030 年將達到 139 億美元。

藥物基因體學技術是指將藥理學和基因組學結合，根據個體的遺傳體質開發個人化醫療的領域。這些技術涉及分析個體的遺傳變異如何影響他們對藥物的反應。了解這些遺傳變異可以幫助醫療保健提供者更好地預測一個人對特定藥物的反應，確定最有效的劑量，並將副作用的風險降至最低。

根據美國癌症協會2022年報告，預計2022年美國將新增190萬癌症病例，其中包括290,560例乳癌病例。

基因組技術的進步

基因組定序和分析技術的進步為市場擴張做出了重大貢獻。次世代定序(NGS)、微陣列分析和生物資訊學工具使得能夠對與藥物反應相關的遺傳變異進行更全面的分析。這些創新將增強精準醫療，最大限度地減少藥物處方中的試驗，並改善患者的治療結果。

資料解釋挑戰

分析遺傳資料很複雜。以臨床實用的方式解釋結果很困難，特別是考慮到涉及大量的遺傳資訊。了解特定基因突變的影響以及它們如何影響藥物反應需要進行高級分析。確保患者基因資訊的安全性和保密性極為重要，但卻很難保證。這些都是阻礙市場成長的因素。

個人化醫療需求不斷成長

藥物基因體學技術透過根據個體的基因譜量身定做治療方法，滿足了對個人化醫療日益成長的需求。這種方法可以提高藥物療效、最大限度地減少副作用並最佳化患者劑量。人們越來越認知到個人化醫療的重要性，個人化醫療根據個人的基因譜量身訂做治療方法。這有利於藥物治療的客製化，以最大限度地提高療效並最大限度地減少副作用。

監管和報銷挑戰

法律規範可能沒有足夠的能力來處理藥物基因組學，導致標準和指南的不確定性。此外，基因檢測和相關服務的報銷可能無法普遍獲得或標準化，從而限制了某些患者的獲得。遺傳資料的序列測定、分析和解釋需要專門的設備和專業知識，而且這個過程非常昂貴。這種成本可能會限制普及和可近性。

COVID-19 的影響：

這次疫情加速了藥物基因體學的研究，並凸顯了個人化醫療的重要性。了解遺傳因素如何影響藥物反應對於開發 COVID-19 的治療方法和疫苗至關重要。在大流行期間，遠端醫療的轉變影響了基因檢測和諮詢的進行方式。遠端醫療服務擴大用於基因檢測和諮詢，允許更廣泛的訪問並最大限度地減少面對面的互動。

腫瘤學領域預計在預測期內規模最大

腫瘤學預計將成為預測期內最大的市場。優點包括個人化治療方法選擇、最大限度地減少副作用、最佳化藥物療效、預測患者反應。這種精確的方法透過改善治療結果、減少試驗和錯誤、根據個別基因圖譜調整治療方法以及推動腫瘤學朝著更有效和個性化的治療方向發展，從而提高患者的生活品質。

預計醫院業在預測期內複合年成長率最高。

預計醫院業在預測期內複合年成長率最高。這種精準醫療方法可以最大限度地減少副作用、提高藥物療效並最佳化劑量。減少試驗試誤並改善患者治療效果，同時最大限度地降低醫療成本。採用這些技術的醫院將受益於個人化的治療計劃、減少的副作用和簡化的劑量策略，確保為患者提供更安全、更有效的護理。

比最大的地區

預計北美在預測期內將佔據最大的市場佔有率。高通量定序技術的發展使得分析個體遺傳資訊變得更加實用且更具成本效益。這使得藥物基因組學在臨床實踐中廣泛應用。人們越來越認知到根據個體的遺傳特徵客製化治療方法以提高藥物療效並儘量減少副作用的重要性。

複合年成長率最高的地區：

由於醫療基礎設施投資增加等多種因素，亞太地區預計在預測期內將維持最高的複合年成長率。該市場包括 DNA序列測定、微陣列技術、聚合酶鍊式反應 (PCR) 和生物資訊學工具等技術，這些技術可分析遺傳變異並根據個人的遺傳特徵定製藥物開發、配方和劑量。支持決策。

免費客製化服務：

訂閱此報告的客戶將收到以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球藥物基因體學技術市場：按類型

  • 生物資訊軟體
  • 臨床決策支援系統
  • 實驗室資訊管理系統
  • 藥物基因組學諮詢
  • 基因檢測服務
  • 樣品製備套件
  • 其他類型

第6章全球藥物基因體學技術市場：依治療領域

  • 神經系統疾病
  • 腫瘤學
    • 乳癌
    • 大腸直腸癌
    • 子宮頸癌
    • 肺癌
  • 免疫疾病
  • 循環系統疾病
  • 感染疾病
  • 其他治療領域

第7章全球藥物基因體學技術市場：依技術分類

  • 順序
  • 免疫組織化學
  • 雜合反應
  • 聚合酶鍊式反應 (PCR)
  • 其他技術

第8章全球藥物基因體學技術市場：按分銷管道分類

  • 零售藥房
  • 醫院藥房
  • 網路藥房

第9章全球藥物基因體學技術市場：依最終用戶分類

  • 醫院
  • 診所
  • 檢查
  • 其他最終用戶

第10章全球藥物基因體學技術市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Phamatech Inc
  • BiogeniQ Inc.
  • CENTOGENE NV
  • Empire Genomics
  • ViennaLab Diagnostics GmbH
  • Thermo Fisher Scientific
  • Admera Health
  • Agena Biosciences Inc.
  • Myriad Genetics Inc.
  • Quest Diagnostics
  • Dynamic DNA Laboratories
  • Personalis Inc.
  • Coriell Life Sciences
  • Illunima Inc
  • OneOme LLC
  • QIAGEN
  • Leica Biosystems
Product Code: SMRC24799

According to Stratistics MRC, the Global Pharmacogenomics Technologies Market is accounted for $6.8 billion in 2023 and is expected to reach $13.9 billion by 2030 growing at a CAGR of 10.7% during the forecast period. Pharmacogenomics technologies refer to a field that combines pharmacology and genomics to develop personalized medicine based on an individual's genetic makeup. These technologies involve analyzing how an individual's genetic variations influence their response to medications. By understanding these genetic variations, healthcare providers can better predict how a person will respond to a particular drug, determine the most effective dosage, and minimize the risk of adverse reactions.

According to the American Cancer Society 2022 report, an estimated 1.9 million new cancer cases will be diagnosed in the United States in 2022, which includes 290,560 cases of breast cancer.

Market Dynamics:

Driver:

Advancements in genomic technologies

Progress in genomic sequencing and analysis technologies has significantly contributed to the expansion of market. Next-generation sequencing (NGS), microarray analysis, and bioinformatics tools enable more comprehensive analysis of genetic variations related to drug response. These innovations enhance precision medicine, minimizing trial and error in prescribing medications and improving patient outcomes.

Restraint:

Data interpretation challenges

Analyzing genetic data is complex. Interpreting the results in a clinically actionable way can be challenging, especially given the vast amount of genetic information involved. Understanding the implications of specific genetic variations and their impact on drug response requires sophisticated analysis. Ensuring the security and confidentiality of patient genetic information is critical but can be difficult to guarantee. These are the factors impeding the growth of the market.

Opportunity:

Increasing demand for personalized medicine

Pharmacogenomics technologies meet the rising demand for personalized medicine by tailoring treatments based on individual genetic profiles. This approach enhances drug efficacy, minimizes adverse reactions, and optimizes dosages for patients. There's a growing recognition of the importance of personalized medicine, which tailors treatments based on individual genetic profiles. It facilitates the customization of drug therapies to maximize efficacy and minimize adverse reactions.

Threat:

Regulatory and reimbursement challenges

Regulatory frameworks may not be fully equipped to handle pharmacogenomics, leading to uncertainties about standards and guidelines. Additionally, reimbursement for genetic testing and related services might not be universally available or standardized, limiting access for some patients. Sequencing, analyzing, and interpreting genetic data require specialized equipment and expertise, making the process costly. This expense can limit widespread adoption and accessibility.

Covid-19 Impact:

The pandemic has accelerated research in pharmacogenomics, emphasizing the importance of personalized medicine. Understanding how genetic factors influence drug response became crucial in developing treatments and vaccines for COVID-19. The shift towards telemedicine during the pandemic affected the way genetic testing and counseling was delivered. There's an increased use of telehealth services for genetic testing and consultations, allowing wider accessibility and minimizing in-person interactions.

The oncology segment is expected to be the largest during the forecast period

The oncology segment is expected to be the largest during the forecast period. Advantages include personalized therapy selection, minimizing adverse reactions, optimizing drug efficacy, and predicting patient response. This precision approach enhances treatment outcomes, reduces trial and error, and improves patient quality of life by matching therapies to individual genetic profiles, advancing oncology towards more effective and personalized care.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. This precision medicine approach minimizes adverse reactions, enhances drug efficacy, and optimizes dosage. It reduces trial-and-error prescribing, improving patient outcomes while minimizing healthcare costs. Hospitals employing these technologies benefit from personalized treatment plans, reduced side effects, and streamlined medication strategies, ensuring safer and more effective care for patients.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The development of high-throughput sequencing techniques has made it more feasible and cost-effective to analyze an individual's genetic information. This has enabled the widespread application of pharmacogenomics in clinical settings. There's a growing recognition of the importance of tailoring medical treatments to an individual's genetic profile to enhance drug efficacy and minimize adverse reactions.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors such as increasing investments in healthcare infrastructure. The market involves various technologies such as DNA sequencing, microarray technology, polymerase chain reaction (PCR), and bioinformatics tools, among others, which are used to analyze genetic variations and aid in drug development, prescription, and dosage determination customized to an individual's genetic profile.

Key players in the market

Some of the key players in Pharmacogenomics Technologies market include Phamatech Inc, BiogeniQ Inc., CENTOGENE N.V., Empire Genomics, ViennaLab Diagnostics GmbH, Thermo Fisher Scientific, Admera Health, Agena Biosciences Inc., Myriad Genetics Inc., Quest Diagnostics, Dynamic DNA Laboratories, Personalis Inc., Coriell Life Sciences, Illunima Inc, OneOme LLC, QIAGEN and Leica Biosystems.

Key Developments:

In April 2023, Leica Biosystems received the clearance for BOND MMR Antibody Panel, which is expected to aid customers by offering the IHC Mismatch Repair (MMR) option when screening patients with colorectal cancer who may have Lynch syndrome.

In January 2023, QIAGEN announced a strategic partnership with Helix a population genomics company to aid companion diagnostics for genetic diseases.

Types Covered:

  • Bioinformatics Software
  • Clinical Decision Support System
  • Laboratory Information Management System
  • Pharmacogenomic Consulting
  • Genetic Testing Services
  • Sample Preparation Kits
  • Other Types

Therapeutic Areas Covered:

  • Neurological Disorders
  • Oncology
  • Immunological Disorders
  • Cardiovascular Disease
  • Infectious Diseases
  • Other Therapeutic Areas

Technologies Covered:

  • Sequencing
  • Immunohistochemistry
  • In-situ Hybridization
  • Polymerase Chain Reaction (PCR)
  • Other Technologies

Distribution Channels Covered:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

End Users Covered:

  • Hospitals
  • Clinics
  • Research Institute
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmacogenomics Technologies Market, By Type

  • 5.1 Introduction
  • 5.2 Bioinformatics Software
  • 5.3 Clinical Decision Support System
  • 5.4 Laboratory Information Management System
  • 5.5 Pharmacogenomic Consulting
  • 5.6 Genetic Testing Services
  • 5.7 Sample Preparation Kits
  • 5.8 Other Types

6 Global Pharmacogenomics Technologies Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 Neurological Disorders
  • 6.3 Oncology
    • 6.3.1 Breast Cancer
    • 6.3.2 Colorectal Cancer
    • 6.3.3 Cervical Cancer
    • 6.3.4 Lung Cancer
  • 6.4 Immunological Disorders
  • 6.5 Cardiovascular Disease
  • 6.6 Infectious Diseases
  • 6.7 Other Therapeutic Areas

7 Global Pharmacogenomics Technologies Market, By Technology

  • 7.1 Introduction
  • 7.2 Sequencing
  • 7.3 Immunohistochemistry
  • 7.4 In-situ Hybridization
  • 7.5 Polymerase Chain Reaction (PCR)
  • 7.6 Other Technologies

8 Global Pharmacogenomics Technologies Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Hospital Pharmacy
  • 8.4 Online Pharmacy

9 Global Pharmacogenomics Technologies Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Research Institute
  • 9.5 Other End Users

10 Global Pharmacogenomics Technologies Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Phamatech Inc
  • 12.2 BiogeniQ Inc.
  • 12.3 CENTOGENE N.V.
  • 12.4 Empire Genomics
  • 12.5 ViennaLab Diagnostics GmbH
  • 12.6 Thermo Fisher Scientific
  • 12.7 Admera Health
  • 12.8 Agena Biosciences Inc.
  • 12.9 Myriad Genetics Inc.
  • 12.10 Quest Diagnostics
  • 12.11 Dynamic DNA Laboratories
  • 12.12 Personalis Inc.
  • 12.13 Coriell Life Sciences
  • 12.14 Illunima Inc
  • 12.15 OneOme LLC
  • 12.16 QIAGEN
  • 12.17 Leica Biosystems

List of Tables

  • Table 1 Global Pharmacogenomics Technologies Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Pharmacogenomics Technologies Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Pharmacogenomics Technologies Market Outlook, By Bioinformatics Software (2021-2030) ($MN)
  • Table 4 Global Pharmacogenomics Technologies Market Outlook, By Clinical Decision Support System (2021-2030) ($MN)
  • Table 5 Global Pharmacogenomics Technologies Market Outlook, By Laboratory Information Management System (2021-2030) ($MN)
  • Table 6 Global Pharmacogenomics Technologies Market Outlook, By Pharmacogenomic Consulting (2021-2030) ($MN)
  • Table 7 Global Pharmacogenomics Technologies Market Outlook, By Genetic Testing Services (2021-2030) ($MN)
  • Table 8 Global Pharmacogenomics Technologies Market Outlook, By Sample Preparation Kits (2021-2030) ($MN)
  • Table 9 Global Pharmacogenomics Technologies Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 10 Global Pharmacogenomics Technologies Market Outlook, By Therapeutic Area (2021-2030) ($MN)
  • Table 11 Global Pharmacogenomics Technologies Market Outlook, By Neurological Disorders (2021-2030) ($MN)
  • Table 12 Global Pharmacogenomics Technologies Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 13 Global Pharmacogenomics Technologies Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 14 Global Pharmacogenomics Technologies Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 15 Global Pharmacogenomics Technologies Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 16 Global Pharmacogenomics Technologies Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 17 Global Pharmacogenomics Technologies Market Outlook, By Immunological Disorders (2021-2030) ($MN)
  • Table 18 Global Pharmacogenomics Technologies Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 19 Global Pharmacogenomics Technologies Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 20 Global Pharmacogenomics Technologies Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
  • Table 21 Global Pharmacogenomics Technologies Market Outlook, By Technology (2021-2030) ($MN)
  • Table 22 Global Pharmacogenomics Technologies Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 23 Global Pharmacogenomics Technologies Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 24 Global Pharmacogenomics Technologies Market Outlook, By In-situ Hybridization (2021-2030) ($MN)
  • Table 25 Global Pharmacogenomics Technologies Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 26 Global Pharmacogenomics Technologies Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 27 Global Pharmacogenomics Technologies Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 28 Global Pharmacogenomics Technologies Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 29 Global Pharmacogenomics Technologies Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 30 Global Pharmacogenomics Technologies Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 31 Global Pharmacogenomics Technologies Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 Global Pharmacogenomics Technologies Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 33 Global Pharmacogenomics Technologies Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 34 Global Pharmacogenomics Technologies Market Outlook, By Research Institute (2021-2030) ($MN)
  • Table 35 Global Pharmacogenomics Technologies Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.